• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $URGN

    UroGen Pharma Ltd.

    Subscribe to $URGN
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: urogen.com

    Peers

    $MEIP
    $KRON

    Recent Analyst Ratings for UroGen Pharma Ltd.

    DatePrice TargetRatingAnalyst
    4/16/2025$23.00Sector Outperform
    Scotiabank
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    8/22/2024$40.00Buy
    Guggenheim
    2/8/2023$35.00 → $10.00Buy → Hold
    Jefferies
    4/27/2022$20.00Buy
    Berenberg
    1/18/2022$50.00 → $34.00Buy
    HC Wainwright & Co.
    See more ratings

    UroGen Pharma Ltd. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

      UroGen (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee (ODAC) meeting on May 21, 2025 to review the new drug application (NDA) for UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. The ODAC meeting will provide an opportunity for independent clinicians and other experts to evaluate the UGN-102 data and make a recommendation to the FDA as to whether the NDA should be approved and under what conditions. The FDA carefully considers

      5/7/25 8:57:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      Conference Call and Webcast Scheduled for Monday, May 12, 2025, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2025 financial results on Monday, May 12, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroG

      5/1/25 4:00:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

      Data Presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with JELMYTO (n=41), the median duration of response was 47.8 months, irrespective o

      4/27/25 4:00:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

      New analysis of patient-reported outcomes from the OPTIMA II, ATLAS and ENVISION studies of UGN-102 presented at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without negatively impacting quality of life.

      4/27/25 1:00:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

      Data Presented at the American Urological Association 2025 Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen's sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). "The median duration of response of tw

      4/27/25 12:30:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

      18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) Data unveiled during a Podium Presentation at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced an updated 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. These data were featured today in

      4/26/25 6:30:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

      UGN-301 was tolerated across all dose levels, with no dose-limiting toxicities or adverse events leading to treatment discontinuation UGN-301 formulated in a reverse thermal gel allowed sustained exposure in the bladder Some patients receiving UGN-301 (zalifrelimab) intravesical solution showed clinical activity at the week 12 disease assessment Data presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the Phase 1 dose-escalation study for UG

      4/26/25 10:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

      18-month duration of response (DOR) data from ENVISION, and integrated patient-reported outcomes (PROs) from UGN-102-treated patients in OPTIMA II, ATLAS and ENVISION in low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Long-term outcomes from the OPTIMA II Phase 2B study of UGN-102 Sub-analysis from a long-term follow-up study to the OLYMPUS trial of JELMYTO® (mitomycin) for pyelocalyceal solution Results of a Phase 1 dose escalation study for UGN-301 UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that data on investigational

      4/14/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

      UGN-102 Pivotal ENVISION trial demonstrated an 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, for patients who achieved a complete response (CR) at three months after the first instillation of UGN-102 New drug application (NDA) for UGN-102 under review by the FDA; Prescription Drug User Fee Act (PDUFA) target action date set for June 13, 2025 Acquired a next-generation investigational oncolytic virus (ICVB-1042) and announced multiple strategic research collaborations in support of long-term growth strategy JELMYTO® achieved net product revenue of $90.4 million in 2024, compared with $82.7 million in 2023, driven by underlying demand revenue growth of 12% for 2

      3/10/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 7 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the continued development of the Company's pipeline. Up to 18,500 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesti

      3/7/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    UroGen Pharma Ltd. Financials

    Live finance-specific insights

    See more
    • UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      Conference Call and Webcast Scheduled for Monday, May 12, 2025, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2025 financial results on Monday, May 12, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroG

      5/1/25 4:00:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

      UGN-102 Pivotal ENVISION trial demonstrated an 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, for patients who achieved a complete response (CR) at three months after the first instillation of UGN-102 New drug application (NDA) for UGN-102 under review by the FDA; Prescription Drug User Fee Act (PDUFA) target action date set for June 13, 2025 Acquired a next-generation investigational oncolytic virus (ICVB-1042) and announced multiple strategic research collaborations in support of long-term growth strategy JELMYTO® achieved net product revenue of $90.4 million in 2024, compared with $82.7 million in 2023, driven by underlying demand revenue growth of 12% for 2

      3/10/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

      Conference Call and Webcast Scheduled for Monday, March 10, 2025, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2024 financial results on Monday, March 10, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately

      2/27/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

      - ICVB-1042 is an Oncolytic Virus Engineered to Selectively Destroy Cancer Cells While Retaining Potency and Trigger a Robust Immune Response - Strategic Research Collaborations Focused on Exploring the Potential of UroGen's Innovative RTGel® Technology to Enhance the Clinical Effectiveness of Multiple Immunotherapies - Conference Call Webcast to be Held Today at 12:00 PM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from

      2/20/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

      Conference Call and Webcast Scheduled for Wednesday, November 6, 2024, at 10:00AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 third quarter financial results on Wednesday, November 6, 2024, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days

      10/30/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

      Conference Call and Webcast Scheduled for Tuesday, August 13, 2024, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2024 financial results on Tuesday, August 13, 2024, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

      8/5/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

      12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13, 2024 ENVISION data expected to support completion of UGN-102 NDA in Q3 2024 Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months in LG-UTUC JELMYTO® demonstrated continued growth with net product sales of $18.8 million in Q1, compared with $17.2 million in Q1 2023 representing ~10% YoY growth IND accepted for UGN-103, next-generation novel mitomycin-based formulation of UGN-102 to treat LG-IR-NMIBC Conference call and webcast to be held today at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biote

      5/13/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

      Conference Call and Webcast Scheduled for Monday, May 13, 2024, at 10:00AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About Ur

      5/3/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

      Initiated submission of a rolling NDA to the FDA for UGN-102; 12-month duration of response data from ENVISION expected to support completion of NDA submission Announced next-generation novel mitomycin-based RTGel formulations for LG-IR-NMIBC and LG-UTUC programs from medac GmbH licensing agreement with potential IP protection until December 2041 JELMYTO® achieved net product revenues of $82.7 million in 2023, an increase of ~28% compared with 2022 Announced signing of a restructured agreement with Pharmakon Advisors that provides more favorable terms and provides UroGen up to an additional $100 million credit facility Conference call and webcast to be held today at 10:00 AM ET

      3/14/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

      Conference Call and Webcast Scheduled for Thursday, March 14, 2024, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2023 financial results on Thursday, March 14, 2024, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approxima

      3/4/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    UroGen Pharma Ltd. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

      SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/18/24 6:16:04 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 7:46:37 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 5:46:12 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 4:47:15 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 12:04:53 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 8:37:20 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 6:44:34 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by UroGen Pharma Ltd.

      SC 13G - UroGen Pharma Ltd. (0001668243) (Subject)

      11/12/24 9:30:37 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by UroGen Pharma Ltd.

      SC 13G - UroGen Pharma Ltd. (0001668243) (Subject)

      11/6/24 1:50:55 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by UroGen Pharma Ltd.

      SC 13G - UroGen Pharma Ltd. (0001668243) (Subject)

      6/24/24 5:25:03 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    UroGen Pharma Ltd. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    UroGen Pharma Ltd. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chief Medical Officer Schoenberg Mark converted options into 8,000 units of Ordinary Shares and sold $50,698 worth of Ordinary Shares (4,551 units at $11.14), increasing direct ownership by 2% to 148,540 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      2/4/25 11:53:22 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Smith Jason Drew converted options into 14,667 units of Ordinary Shares and sold $82,202 worth of Ordinary Shares (7,379 units at $11.14), increasing direct ownership by 29% to 32,514 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      2/4/25 11:51:51 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Barrett Elizabeth A.

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      2/4/25 11:49:08 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Degnan Chris

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      10/9/24 4:22:54 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Degnan Chris

      3 - UroGen Pharma Ltd. (0001668243) (Issuer)

      10/9/24 4:21:47 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Schoenberg Mark converted options into 1,666 units of Ordinary Shares and sold $11,236 worth of Ordinary Shares (859 units at $13.08), increasing direct ownership by 0.56% to 145,091 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      9/12/24 1:54:09 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Smith Jason Drew sold $19,895 worth of Ordinary Shares (1,521 units at $13.08) and converted options into 3,333 units of Ordinary Shares, increasing direct ownership by 8% to 25,226 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      9/12/24 1:51:58 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kim Dong converted options into 2,500 units of Ordinary Shares, increasing direct ownership by 7% to 37,753 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      9/12/24 1:50:15 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Belldegrun Arie

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      8/8/24 9:11:37 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cohen Fred E

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      8/8/24 9:11:08 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on UroGen Pharma with a new price target

      Scotiabank initiated coverage of UroGen Pharma with a rating of Sector Outperform and set a new price target of $23.00

      4/16/25 8:14:26 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on UroGen Pharma with a new price target

      Ladenburg Thalmann resumed coverage of UroGen Pharma with a rating of Buy and set a new price target of $31.00

      2/19/25 7:08:16 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on UroGen Pharma with a new price target

      Guggenheim initiated coverage of UroGen Pharma with a rating of Buy and set a new price target of $40.00

      8/22/24 7:38:58 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma downgraded by Jefferies with a new price target

      Jefferies downgraded UroGen Pharma from Buy to Hold and set a new price target of $10.00 from $35.00 previously

      2/8/23 7:33:16 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on UroGen Pharma with a new price target

      Berenberg initiated coverage of UroGen Pharma with a rating of Buy and set a new price target of $20.00

      4/27/22 7:19:23 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on UroGen Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of UroGen Pharma with a rating of Buy and set a new price target of $34.00 from $50.00 previously

      1/18/22 10:02:20 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on UroGen Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of UroGen Pharma with a rating of Buy and set a new price target of $50.00 from $57.00 previously

      4/27/21 6:32:36 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright resumed coverage on UroGen Pharma

      HC Wainwright resumed coverage of UroGen Pharma with a rating of Buy

      3/16/21 7:40:52 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    UroGen Pharma Ltd. SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by UroGen Pharma Ltd.

      10-K/A - UroGen Pharma Ltd. (0001668243) (Filer)

      4/30/25 4:00:34 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by UroGen Pharma Ltd.

      SCHEDULE 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      3/17/25 1:23:02 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by UroGen Pharma Ltd.

      10-K - UroGen Pharma Ltd. (0001668243) (Filer)

      3/10/25 4:32:40 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      3/10/25 8:02:05 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      2/20/25 8:05:11 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by UroGen Pharma Ltd.

      SCHEDULE 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      2/12/25 9:34:06 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by UroGen Pharma Ltd.

      SCHEDULE 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      2/5/25 10:09:20 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Ltd. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      1/14/25 7:01:05 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by UroGen Pharma Ltd.

      10-Q - UroGen Pharma Ltd. (0001668243) (Filer)

      11/6/24 8:04:11 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      11/6/24 8:01:53 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    UroGen Pharma Ltd. Leadership Updates

    Live Leadership Updates

    See more
    • UroGen Appoints Chris Degnan as Chief Financial Officer

      Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc

      10/9/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Appoints David Lin as New Chief Commercial Officer

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U

      6/3/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

      IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023. "I am pleased to welcome Jim to our Board and look forward to working with him," said David-Alexandre C. Gros, M.D., Chief Executive Officer. "Jim joins our Board at a pivotal time in our mission to bring a novel and much-needed new treatm

      9/11/23 7:00:00 AM ET
      $ELDN
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of James Robinson, former President and Chief Executive Officer (CEO) of Urovant Sciences, to its Board of Directors, effective immediately. "We are thrilled to welcome Jim to the Board of Directors," said Liz Barrett, President and Chief Executive Officer of UroGen. "His proven leadership, operational and commercial experience will provide valuable guidance as we look to expand access to JELMYTO and advance our lead clinical development program, UGN-102 in low-grade intermediate risk bladder cancer, to

      7/25/23 4:10:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dan Wildman to its Board of Directors, effective immediately. Dan Wildman, Chairman of the Board of Progenerative Medical, Inc., a 40-year veteran of the medical device industry, and Strategic Advisor to several medical device and pharmaceutical companies, has agreed to join UroGen's board, effective immediately. Dan spent most of his career with Johnson & Johnson, where he most recently led the Digital Surgery Strategy Initiative that developed an integrated strategy for robotic surgery for the Compa

      11/9/22 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dr. Leana S. Wen to its Board of Directors, effective immediately. Dr. Leana S. Wen, an emergency medicine physician and public health and policy expert, has agreed to join UroGen's board, effective immediately. She has served as a professor of health policy and management at the George Washington University School of Public Health since September 2019. "We are fortunate to welcome Dr. Wen to UroGen's Board of Directors," said Liz Barrett, President and Chief Executive Officer, UroGen. "Dr. Wen's wor

      9/12/22 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

      FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.       Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has

      3/22/22 8:02:00 AM ET
      $CALT
      $PHAT
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

      PRINCETON, N.J. & HOUSTON--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC). UroGen’s approach involves the local delivery of potent immunomodulators (UGN-201, a TLR 7/8 agonist and UGN-301, an anti-CTLA-4 antibody). UGN-301, an immune checkpoint inhibitor

      1/13/21 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology

      PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the presentation of final data from the UGN-101 Jelmyto® (mitomycin) for pyelocalyceal solution Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC). The results will be presented as a virtual podium presentation at the 21st Annual Meeting of the Society of Urologic Oncology (SUO): Oral Session: Best of Bladder Cancer Abstract #: 1003 Title: Durability of Response to Chemoablative Treatment of Low-Grade Upper Tract Urotheli

      12/3/20 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care